Phase 1/2 Evaluation of Intratumoral INT230-6 for the Treatment of Solid Tumors
Phase 1/2 trial evaluating intratumoral administration of INT230-6 alone and in combination with an anti-PD1 antibody for advanced malignancies. TPS2609
Tumor cell death caused by INT230-6 induces protective T cell immunity.
Intratumoral injection of INT230-6 induces protective T cell immunity.
A novel immunotherapy, INT230-6, is able to induce high rates of complete and durable response in mice through a cytotoxic T-cell-dependent mechanism
Novel Drug, INT230-6 shows strong synergy with anti-PD-1 Antibodies and can induce high complete response rates with T-cell memory response in a colon cancer mouse model
INT230-6, a Novel Intratumoral Anticancer Agent, is able to Eradicate Large Established Tumors and Stimulate Potent Antitumor Immunity
Novel cell penetrating formulation of cytotoxic agents administered intratumorally causes complete regression of large tumors and stimulation of an adaptive immune response in BALB/c syngeneic mice inoculated subcutaneously with murine CT26 colon cancer